|

nab-Paclitaxel+carboplatin Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Also known as: nab-Paclitaxel group

Pipeline

Phase 2: 2Phase 3: 1Phase 2/3: 1

Top Sponsors

  • Hebei Medical University Fourth Hospital2
  • Shengjing Hospital1
  • Eikon Therapeutics1

Indications

  • Cancer4
  • Breast Cancer3
  • Nab-paclitaxel2
  • Triple Negative Breast Cancer2
  • Non Small Cell Lung Cancer (Squamous or Non Squamous)1

Other3 trials

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
Phase 2
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Phase 2
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
Phase 3

Mineola, New York1 trial

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NYU Langone Hospital Long Island

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.